Daudi Cells
Essential facts about Daudi cells
Description | The Daudi cell line was established in 1967 from a 16-year-old African boy diagnosed with Burkitt's Lymphoma, a type of lymphoma. Named after the patient from whom it was derived, the Daudi cell line is characterized by its Epstein-Barr Virus (EBV) positivity, a common feature in Burkitt's lymphoma and several other lymphoproliferative disorders. The EBV infection within these cells offers a unique model for studying the virus's role in tumorigenesis, particularly in the context of B-cell malignancies. Daudi human cells lack expression of the classical Major Histocompatibility Complex (MHC) class I molecules on their surface, which is attributed to the absence of beta-2-microglobulin, a crucial component responsible for the correct intracellular folding and processing of the MHC class I molecule in the endoplasmic reticulum. The lack of beta-2-microglobulin in the Daudi cell line leads to a lack of glycosyl modifications necessary for proper cell surface expression of these molecules. The Daudi cell line is extensively utilized in immunology research, particularly in studies involving the immunodepletion of lymphocyte subpopulations, including lymphocytes, natural killer cells, and peripheral blood mononuclear cells. In summary, the Daudi cell line serves as a critical resource for advancing our knowledge in various research fields, from the basic understanding of cell biology to the development of targeted therapies for cancer treatment. |
---|---|
Organism | Human |
Tissue | Blood |
Disease | Burkitt lymphoma |
Applications | Analysis of B cell surface antigens, testing of cytotoxic drugs, mutational analysis, analysis of apoptotic mechanisms, assay development. |
Synonyms | DAUDI, NK-10A, NK-10a, NK 10a, NK10a, N, GM03190, GM3190, GM03190A, GM17346 |
Details
Age | 16 years |
---|---|
Gender | Male |
Ethnicity | African |
Morphology | Round cells |
Cell type | B lymphoblast |
Growth properties | Suspension |
Identifiers
Citation | Daudi (Cytion catalog number 302009) |
---|---|
Biosafety level | Daudi cells do not release Epstein-Barr virus (EBV) when cultured, classifying them as Risk Group 1. However, when used for genetic experiments, they should be treated as Risk Group 2 cells. |
Genetics
Antigen expression | CD10+, CD19+, CD20+, CD21+, CD22+, CD23-, CD24-, CD32+, CD37+, CD38+, CD39-,CD40+, CD54+, CD72+, CD73-, CD75+, CD77+, CD81+, CD82+, CD83-, CD84+, CD86+ |
---|---|
Karyotype | 46, almost diploid |
Daudi cell line culturing methods
Culture Medium | RPMI 1640, w: 2.1 mM stable Glutamine, w: 2.0 g/L NaHCO3 (Cytion article number 820700a) |
---|---|
Medium supplements | Supplement the medium with 10% FBS |
Subculturing | Maintain cultures by periodically adding or replacing the medium. Initiate cultures with a density of 2 x 10^5 cells/ml and keep the cell concentration within the range of 1 x 10^5 to 1 x 10^6 cells/ml for optimal growth. |
Seeding density | 3 x 10^5 cells/ml |
Fluid renewal | 2 times per week |
Freezing recovery | Fast (48 hours) |
Freeze medium | CM-1 (Cytion catalog number 800100) or CM-ACF (Cytion catalog number 806100) |
Handling of cryopreserved cultures |
|
Quality control of Daudi cells
Sterility | Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods. To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections. |
---|---|
STR profile |
Amelogenin: x,y
CSF1PO: 12
D13S317: 11,12
D16S539: 10,12
D5S818: 8,13
D7S820: 8,10
TH01: 6,7
TPOX: 8,11
vWA: 15,17
D3S1358: 16,18
D21S11: 34,35
D18S51: 16,18
Penta E: 7,9
Penta D: 10,12
D8S1179: 14
FGA: 21,26
D19S433: 12,14
|
HLA alleles |
A*: 01:02, 02.01.1900 18:01
B*: 02.01.1900 10:01, 02.01.1900 10:02
C*: 03:02:02, 06:02:01
DRB1*: 13:01:01, 13:02:01
DQA1*: 01:02:01, 01:03:01
DQB1*: 06:02:01, 06:04:01
DPB1*: 02:01:02, 106:01
E: 01:03:02, 01:03:05
|